The CW10 monoclonal antibody specifically binds to HVEM (Herpes virus entry mediator). HVEM is also known as CD270, Tumor necrosis factor receptor-like 2 (TR2), or LIGHT Receptor (LIGHT-R). CD270 is a type I transmembrane protein and member of the TNF Receptor superfamily. It is encoded by TNFRSF14 (tumor necrosis factor receptor superfamily member 14). CD270 is expressed on T cells, B cells, NK cells, monocytes, granulocytes, and some dendritic cells. CD270 binds to Lymphotoxin α (LTa3/TNFβ), CD258/LIGHT, CD272/BTLA, and glycoprotein D of Herpes simplex viruses HSV-1 and HSV-2. CD270-LIGHT interactions can reportedly transduce costimulatory signals for T cells whereas CD270-BTLA interactions can deliver inhibitory signals to T cells.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system or other oligo-dT-based capture systems. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.